As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Replimune Group Inc. The largest reported stake is Baker Bros. Advisors LP's, at 11.8%. 16 filings are on record since July 31, 2025 (Schedule 13D/A, August 11, 2026).
Sell to companies like Replimune Group Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: The Goldman Sachs Group, Inc. · Sole voting: 0 · Shared voting: 3,115,199 · Sole dispositive: 0 · Shared dispositive: 3,115,243 · SCHEDULE 13G/A, 2026-11-09
- · Reporting person: Ridgeback Capital Investments L.P. · Sole voting: 0 · Shared voting: 7,310,656 · Sole dispositive: 0 · Shared dispositive: 7,310,656 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Baker Bros. Advisors LP · Sole voting: 11,075,336 · Shared voting: 0 · Sole dispositive: 11,075,336 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-11
- · Holder: The Goldman Sachs Group, Inc. · Percent: 5.3% · SCHEDULE 13G
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 4,344,038 · Sole dispositive: 0 · Shared dispositive: 4,440,144 · SCHEDULE 13G, 2026-08-07
Replimune Group Inc has 16 Schedule 13D or 13G filings on record since 2025-07-31. 5 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 11.8% | 11,075,336 | SCHEDULE 13D/A, 2026-08-11 | 2026-08-09 |
| RTW Investments, LP | 8.9% | 7,356,916 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Ridgeback Capital Investments L.P. | 8.7% | 7,310,656 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Montanova Capital, LLC | 7.9% | 6,609,000 | SCHEDULE 13G/A, 2026-08-06 | 2026-07-30 |
| State Street Corporation | 5.3% | 4,440,144 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Point72 Asset Management, L.P. | 4.7% | 3,629,902 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Forbion Capital Fund III Cooperatief U.A. | 3.5% | 2,808,368 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Goldman Sachs Group, Inc. | 3.3% | 3,115,243 | SCHEDULE 13G/A, 2026-11-09 | 2026-09-30 |
| Redmile Group, LLC | 0.7% | 535,818 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| T. Rowe Price Associates, Inc. | 0.2% | 157,965 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
Holding shares or following this stake? See who's behind Replimune Group Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Replimune Group Inc and the records around it.
Replimune Group Inc elsewhere on the record
Companies that share a holder
- Ridgeback Capital Investments L.P. also filed stake reports on 3 other companies: Lenz Therapeutics, Inc. (Feb 2026), iTeos Therapeutics, Inc. (Nov 2025), Semler Scientific, Inc. (Nov 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026), Nurix Therapeutics, Inc. (Aug 2026)
- Montanova Capital, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Replimune Group Inc
Get an email when Replimune Group Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Replimune Group Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Replimune Group Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Replimune Group Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 11,075,336 | 0 | 11,075,336 | 0 | SCHEDULE 13D/A, 2026-08-11 |
| Baker Bros. Advisors (GP) LLC | 11,075,336 | 0 | 11,075,336 | 0 | SCHEDULE 13D/A, 2026-08-11 |
| Julian C. Baker | 11,075,336 | 0 | 11,075,336 | 0 | SCHEDULE 13D/A, 2026-08-11 |
| Felix J. Baker | 11,075,336 | 0 | 11,075,336 | 0 | SCHEDULE 13D/A, 2026-08-11 |
| Ridgeback Capital Investments L.P. | 0 | 7,310,656 | 0 | 7,310,656 | SCHEDULE 13G/A, 2026-08-14 |
| Ridgeback Capital Investments LLC | 0 | 7,310,656 | 0 | 7,310,656 | SCHEDULE 13G/A, 2026-08-14 |
| Ridgeback Capital Management LLC | 0 | 7,310,656 | 0 | 7,310,656 | SCHEDULE 13G/A, 2026-08-14 |
| Montanova Capital, LLC | 0 | 6,609,000 | 0 | 6,609,000 | SCHEDULE 13G/A, 2026-08-06 |
| Averill Master Fund, Ltd. | 0 | 5,610,970 | 0 | 5,610,970 | SCHEDULE 13G/A, 2026-08-06 |
| Aaron Cowen | 0 | 6,609,000 | 0 | 6,609,000 | SCHEDULE 13G/A, 2026-08-06 |
| State Street Corporation | 0 | 4,344,038 | 0 | 4,440,144 | SCHEDULE 13G, 2026-08-07 |
| The Goldman Sachs Group, Inc. | 0 | 3,115,199 | 0 | 3,115,243 | SCHEDULE 13G/A, 2026-11-09 |
| Goldman Sachs & Co. LLC | 0 | 3,115,199 | 0 | 3,115,243 | SCHEDULE 13G/A, 2026-11-09 |
The latest filing identifies Replimune Group Inc by CUSIP 76029N106 and gives its principal executive office as 500 Unicorn Park Drive, Suite 303, Woburn (SCHEDULE 13G/A, 2026-11-09).
Source of funds (Item 3)
Item 3 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 4 below is incorporated herein by reference.Baker Bros. Advisors LP, SCHEDULE 13D/A, 2026-08-11
Purpose of Transaction (Item 4)
Baker Bros. Advisors LP
Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosures in Item 5 and Item 6 below are incorporated herein by reference. On August 9, 2026, Replimune Group, Inc. (the "Issuer") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (collectively, the "Underwriters"), related to the public offering (the "Offering") of 9,701,490 shares of common stock of the Issuer ("Common Stock") at a price to the public of $12.06 per share and 2,736,340 pre-funded warrants at a price to the public of $12.0599 per pre-funded warrant to purchase shares of Common Stock that are exercisable at any time on a 1-for-1 basis into Common Stock at an exercise price of $0.0001 per warrant with no expiration date, subject to beneficial ownership limitations described in Item 5 (the "2026 $0.0001 Prefunded Warrants"). The Offering closed on August 11, 2026. Pursuant to the Offering, 667 and Life Sciences purchased 126,394 and 2,609,946 2026 $0.0001 Prefunded Warrants, respectively, at the offering price of $12.0599 per pre-funded warrant, totaling 2,736,340 2026 $0.0001 Prefunded Warrants in the aggregate for an aggregate purchase price of $32,999,986.77. Each of 667 and Life Sciences purchased the 2026 $0.0001 Prefunded Warrants with its working capital. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-11; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-31 | Point72 Asset Management, L.P. | 5.7% | SCHEDULE 13G |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 10.6% | SCHEDULE 13G/A |
| 2025-11-14 | Point72 Asset Management, L.P. | 4.7% | SCHEDULE 13G/A |
| 2025-11-14 | Redmile Group, LLC | 0.7% | SCHEDULE 13G/A |
| 2025-11-14 | RTW Investments, LP | 8.2% | SCHEDULE 13G |
| 2026-02-17 | Forbion Capital Fund III Cooperatief U.A. | 3.5% | SCHEDULE 13G/A |
| 2026-05-07 | T. Rowe Price Associates, Inc. | 0.2% | SCHEDULE 13G/A |
| 2026-05-12 | Suvretta Capital Management, LLC | 5.1% | SCHEDULE 13G |
| 2026-05-15 | RTW Investments, LP | 8.9% | SCHEDULE 13G/A |
| 2026-05-21 | Ridgeback Capital Investments L.P. | 7.6% | SCHEDULE 13G |
| 2026-08-06 | Montanova Capital, LLC | 7.9% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 5.3% | SCHEDULE 13G |
| 2026-08-10 | The Goldman Sachs Group, Inc. | 5.3% | SCHEDULE 13G |
| 2026-08-11 | Baker Bros. Advisors LP | 11.8% | SCHEDULE 13D/A |
| 2026-08-14 | Ridgeback Capital Investments L.P. | 8.7% | SCHEDULE 13G/A |
| 2026-11-09 | The Goldman Sachs Group, Inc. | 3.3% | SCHEDULE 13G/A |
Questions about who owns Replimune Group Inc
Who owns Replimune Group Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Replimune Group Inc: Baker Bros. Advisors LP (11.8%, Schedule 13D/A, filed 2026-08-11), RTW Investments, LP (8.9%, Schedule 13G/A, filed 2026-05-15), Ridgeback Capital Investments L.P. (8.7%, Schedule 13G/A, filed 2026-08-14), Montanova Capital, LLC (7.9%, Schedule 13G/A, filed 2026-08-06) and State Street Corporation (5.3%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Replimune Group Inc?
By the share each holder's latest filing reports, the largest holders of Replimune Group Inc on this page are Baker Bros. Advisors LP (11.8%), RTW Investments, LP (8.9%) and Ridgeback Capital Investments L.P. (8.7%).
When did Baker Bros. Advisors LP buy into Replimune Group Inc?
The filings give report dates, not purchase dates. The earliest filing from Baker Bros. Advisors LP on this page is the Schedule 13D/A, filed 2026-08-11, reporting 11.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Replimune Group Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.